- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04905914
Study Of ATRN-119 In Patients With Advanced Solid Tumors
March 8, 2024 updated by: Aprea Therapeutics
A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of Oral ATRN-119 In Patients With Advanced Solid Tumors
The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid tumors.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
45
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Crystal Miller, RN BSN
- Phone Number: 1 617 463 9385
- Email: crystal.miller@aprea.com
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520-8028
- Recruiting
- Yale Cancer Center
-
Principal Investigator:
- Patricia LoRusso, MD
-
Contact:
- Ingrid Palma
-
Contact:
- Email: Ingrid.palma@yale.edu
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Recruiting
- University Hospitals, Cleveland Medical Center
-
Contact:
- Amit Mahipal, MD
- Phone Number: 800-641-2422
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
-
Contact:
- Fiona Simpkins, MD
- Phone Number: 215-220-9519
- Email: PerelmanGyn/OncResearchCoordinatorPool@uphs.upenn.edu
-
-
Texas
-
Dallas, Texas, United States, 75230
- Active, not recruiting
- Mary Crowley Cancer Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- DNA damage response (DDR) mutations documented in the past medical record or confirmed during the screening period.
- Measurable disease defined by RECIST 1.1.
- Life expectancy ≥ 3 months.
- Subject must be capable of oral administration of study medication.
Exclusion Criteria:
- Subject has had a cytotoxic chemotherapy, immunotherapy, radiotherapy or other targeted therapies within 4 weeks.
- Surgical procedure performed within 7 days prior to first scheduled dose of ATRN-119.
- Concomitant treatment with strong inhibitors or inducers of CYP3A4 and CYP2D6.
- Known human immunodeficiency virus infection (HIV).
- Subjects with active viral or bacterial infections and/or receiving systemic antibiotics or anti-viral medications.
- Current or past diagnosis of leukemia within the past 5 years.
- Prior radiotherapy at the target lesion unless there is evidence of disease progression.
- Known CNS metastases or clinical evidence of CNS involvement that is not stable for previous 1 month by radiology documentation (magnetic resonance imaging [MRI] brain).
- History of non-malignant gastronintestinal (GI) bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3-months.
- Patient has uncontrolled hypertension at time of enrollment.
- Complete left bundle branch block (LBBB), bifascicular block (right bundle branch block [RBBB] with either left anterior hemiblock or left posterior hemiblock).
- Any clinically significant ST segment and/or T-wave abnormalities.
- Myocardial infarction or unstable angina pectoris within 6 months prior to starting study medication.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 50mg ATRN-119
Once daily oral administration.
|
ATRN-119 is a capsule formulation that will be supplied as 50 mg and 200 mg hydroxymethyl cellulose (HPMC) capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.
|
Experimental: 100mg ATRN-119
Once daily oral administration.
|
ATRN-119 is a capsule formulation that will be supplied as 50 mg and 200 mg hydroxymethyl cellulose (HPMC) capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.
|
Experimental: 200mg ATRN-119
Once daily oral administration.
|
ATRN-119 is a capsule formulation that will be supplied as 50 mg and 200 mg hydroxymethyl cellulose (HPMC) capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.
|
Experimental: 350mg ATRN-119
Once daily oral administration.
|
ATRN-119 is a capsule formulation that will be supplied as 50 mg and 200 mg hydroxymethyl cellulose (HPMC) capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.
|
Experimental: 550mg ATRN-119
Once daily oral administration.
|
ATRN-119 is a capsule formulation that will be supplied as 50 mg and 200 mg hydroxymethyl cellulose (HPMC) capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.
|
Experimental: 800mg ATRN-119
Once daily oral administration.
|
ATRN-119 is a capsule formulation that will be supplied as 50 mg and 200 mg hydroxymethyl cellulose (HPMC) capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Emergent Adverse Events (TEAEs) will be collected and evaluated based on summary statistics
Time Frame: Day 1 to Day 56
|
Treatment-emergent AEs (TEAEs) will be collected and Clinical Laboratory Evaluations will be performed
|
Day 1 to Day 56
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Crystal Miller, RN BSN, Aprea Therapeutics Inc
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 9, 2023
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
May 17, 2021
First Submitted That Met QC Criteria
May 24, 2021
First Posted (Actual)
May 28, 2021
Study Record Updates
Last Update Posted (Actual)
March 12, 2024
Last Update Submitted That Met QC Criteria
March 8, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AR-276-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
GI Innovation, Inc.RecruitingAdvanced Solid Tumor | Metastatic Solid TumorKorea, Republic of, United States
-
Xenthera, Inc.Not yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on ATRN-119
-
PegBio Co., Ltd.Tigermed Consulting Co., LtdCompletedType 2 Diabetes MellitusChina
-
Dongkook Pharmaceutical Co., Ltd.Active, not recruiting
-
PegBio Co., Ltd.CompletedType2 Diabetes MellitusUnited States
-
Taiho Oncology, Inc.TerminatedAdvanced Solid TumorsItaly, Spain, United States, Netherlands, United Kingdom
-
InQpharm GroupCompletedUpper Respiratory Tract SymptomsGermany
-
PegBio Co., Ltd.Not yet recruiting
-
argenxRecruiting
-
PegBio Co., Ltd.Completed
-
AmgenSuspendedA Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLCSmall Cell Lung CancerUnited States
-
PegBio Co., Ltd.CovanceCompletedType 2 Diabetes Mellitus (T2DM)United States